Simultaneous estimation of raloxifene and cladrin by HPLC: application to metabolic stability studies in different species

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Palomba S, Numis FG, Mossetti G et al. Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum. Reprod. 18(1), 192–198 (2003). •• Study describes the treatment of raloxifene against osteoporosis in menopausal women.
  Medline CASGoogle Scholar
• 2. Kanis JA, Johnell O, Black DM et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33(3), 293–300 (2003).
  Medline CASGoogle Scholar
• 3. Bryant HU, Glasebrook AL, Yang NN, Sato M. An estrogen receptor basis for raloxifene action in bone. J. Steroid Biochem. Mol. Biol. 69(1-6), 37–44 (1999).
  Medline CASGoogle Scholar
• 4. Dane C, Dane B, Cetin A, Erginbas M. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis. Gynecol. Endocrinol. 23(7), 398–403 (2007).
  Medline CASGoogle Scholar
• 5. Avioli LV. SERM drugs for the prevention of osteoporosis. Trends Endocrinol. Metab. 10(8), 317–319 (1999).
  Medline CASGoogle Scholar
• 6. Yao Z, Shen X, Capodanno I et al. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J. Investig Surg. 18(4), 177–183 (2005).
  Medline CASGoogle Scholar
• 7. Hong N, Shin S, Lee S, Kim KJ, Rhee Y. Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis. Calcif. Tissue Int. 111(1), 47–55 (2022).
  Medline CASGoogle Scholar
• 8. Peres-Ueno MJ, Fernandes F, Brito VGB et al. Effect of pre-treatment of strength training and raloxifene in periestropause on bone healing. Bone 134(February), 1–15 (2020).
  Google Scholar
• 9. Furusyo N, Ogawa E, Sudoh M et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J. Hepatol. 57(6), 1186–1192 (2012).
  Medline CASGoogle Scholar
• 10. Hibner M, Magrina JF, Lefler SR, Cornella JL, Pizarro AR, Loftus JC. Effects of raloxifene hydrochloride on endometrial cancer cells in vitro. Gynecol. Oncol. 93(3), 642–646 (2004).
  Medline CASGoogle Scholar
• 11. Beekman KM, Veldhuis-Vlug AG, den Heijer M et al. The effect of raloxifene on bone marrow adipose tissue and bone turnover in postmenopausal women with osteoporosis. Bone 118, 62–68 (2019).
  Medline CASGoogle Scholar
• 12. Fontana MC, Laureano JV, Forgearini B et al. Spray-dried raloxifene submicron particles for pulmonary delivery: development and in vivo pharmacokinetic evaluation in rats. Int. J. Pharm. 585(May), 1–8 (2020).
  Google Scholar
• 13. Rai R, Singh KB, Khanka S, Maurya R, Singh D. Cladrin alleviates dexamethasone-induced apoptosis of osteoblasts and promotes bone formation through autophagy induction via AMPK/mTOR signaling. Free Radic. Biol. Med. 190, 339–350 (2022). •• The study explains cladrin-enhanced bone formation in postmenopausal women.
  Medline CASGoogle Scholar
• 14. Chauhan D, Sultana N, Yadav PK et al. Pharmacokinetic interaction potential assessment of cladrin, a potent bioactive constituent of Butea monosperma, and raloxifene, a prescription anti-osteoporotic by in vitro ADME approach. Indian J. Tradit. Knowl. 21(4), 789–796 (2022). • Chromatographic resolution of raloxifene and cladrin using HPLC chromatographic conditions.
  Google Scholar
• 15. Maurya R, Yadav DK, Singh G et al. Osteogenic activity of constituents from Butea monosperma. Bioorganic Med. Chem. Lett. 19(3), 610–613 (2009).
  Medline CASGoogle Scholar
• 16. Rashid M, Singh SK, Malik MY et al. Development and validation of UPLC–MS/MS assay for quantification of cladrin: absolute bioavailability and dose proportionality study in rats. J. Pharm. Biomed. Anal. 152, 289–297 (2018). •• Chromatographic conditions of cladrin using LC–MS/MS.
  Medline CASGoogle Scholar
• 17. Karia P, Patel KV, Rathod SSP. Breast cancer amelioration by Butea monosperma in-vitro and in-vivo. J. Ethnopharmacol. 217, 54–62 (2018).
  MedlineGoogle Scholar
• 18. Trontelj J, Vovk T, Bogataj M, Mrhar A. HPLC analysis of raloxifene hydrochloride and its application to drug quality control studies. Pharmacol. Res. 52(4), 334–339 (2005).
  Medline CASGoogle Scholar
• 19. Basavaiah K, Kumar URA, Tharpa K. Gradient HPLC analysis of raloxifene hydrochloride and its application to drug quality control. Acta Pharm. 58(3), 347–356 (2008).
  Medline CASGoogle Scholar
• 20. Pritchard T, Rosengren RJ, Greish K, Taurin S. Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer. J. Drug Target 24(5), 441–449 (2016).
  Medline CASGoogle Scholar
• 21. Boto REF, Almeida P, Queiroz JA. Thiacarbocyanine as ligand in dye-affinity chromatography. Biomed. Chromatogr. 288(3), 278–288 (2008).
  Google Scholar
• 22. ICH. Methodology validation of analytical procedures. Ich. Harmon. Tripart Guidel. (November), 41–50 (1996). •• Guidelines used for the analytical method development and its validation.
  Google Scholar
• 23. Saklani R, Tiwari AK, Yadav PK, Yadav P, Chourasia MK. Validated HPLC–UV method for simultaneous estimation of paclitaxel and doxorubicin employing ion pair chromatography: application in formulation development and pharmacokinetic studies. Biomed. Res. Int. 2022, 1–11 (2022).
  Google Scholar
• 24. Singh Y, Chandrashekar A, Pawar VK et al. Novel validated RP-HPLC Method for bendamustine hydrochloride based on ion-pair chromatography: application in determining infusion stability and pharmacokinetics. J. Chromatogr. Sci. 55(1), 30–39 (2017).
  Medline CASGoogle Scholar
• 25. Yadav PK, Tiwari AK, Saklani R et al. HPLC method for simultaneous estimation of paclitaxel and baicalein: pharmaceutical and pharmacokinetic applications. Bioanalysis 14(14), 1005–1020 (2022).
  CASGoogle Scholar
• 26. Kamal MM, Nazzal S. Development and validation of a HPLC–UV method for the simultaneous detection and quantification of paclitaxel and sulforaphane in lipid based self-microemulsifying formulation. J. Chromatogr. Sci. 57(10), 931–938 (2019).
  CASGoogle Scholar
• 27. Ahmad AM. Potential pharmacokinetic interactions between antiretrovirals and medicinal plants used as complementary and African traditional medicines. Biopharm. Drug Dispos. 28(3), 135–143 (2007).
  Medline CASGoogle Scholar
• 28. Singh SK, Valicherla GR, Bikkasani AK et al. Elucidation of plasma protein binding, blood partitioning, permeability, CYP phenotyping and CYP inhibition studies of withanone using validated UPLC method: an active constituent of neuroprotective herb Ashwagandha. J. Ethnopharmacol. 270(July 2019), 113819 (2021).
  Medline CASGoogle Scholar
• 29. Richert L, Binda D, Hamilton G et al. Evaluation of the effect of culture configuration on morphology, survival time, antioxidant status and metabolic capacities of cultured rat hepatocytes. Toxicol. Vitr. 16(1), 89–99 (2002).
  Medline CASGoogle Scholar
• 30. Ezzeldin E, Iqbal M, Herqash RN, ElNahhas T. Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC–MS/MS method and its application to human microsomal metabolic stability study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1136, 121851 (2020).
  Medline CASGoogle Scholar
• 31. Li W, Zhang J, Wang Y, Hu F, Zhang Y. Metabolism of vesatolimod in rat, dog, and human liver microsomes: metabolic stability assessment, metabolite identification, and interspecies comparison. Drug Test Anal. 11(2), 240–249 (2019).
  Medline CASGoogle Scholar
• 32. Huang M, Ho PC. Identification of metabolites of meisoindigo in rat, pig and human liver microsomes by UFLC–MS/MS. Biochem. Pharmacol. 77(8), 1418–1428 (2009).
  Medline CASGoogle Scholar
• 33. Zhao HY, Hu H, Wang YT. Comparative metabolism and stability of andrographolide in liver microsomes from humans, dogs and rats using ultra-performance liquid chromatography coupled with triple-quadrupole and Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun. Mass Spectrom. 27(12), 1385–1392 (2013). • The study focused on the comparative metabolic profile in different species' liver microsomes.
  Medline CASGoogle Scholar
• 34. Li Z, Zhao S, Yuan Y et al. In vitro metabolic profiles of motolimod by using liquid chromatography tandem mass spectrometry: metabolic stability, metabolite characterization and species comparison. J. Pharm. Biomed. Anal. 167, 90–99 (2019).
  Medline CASGoogle Scholar
• 35. Attwa MW, AlRabiah H, Mostafa GAE, Kadi AA. Development of an LC–MS/MS method for quantification of sapitinib in human liver microsomes: in silico and in vitro metabolic stability evaluation. Molecules 28(5), 1–13 (2023).
  Google Scholar
• 36. Alrabiah H, Kadi AA, Attwa MW, Mostafa GAE. Development and validation of an HPLC–MS/MS method for the determination of arginine-vasopressin receptor blocker conivaptan in human plasma and rat liver microsomes: application to a metabolic stability study. Chem. Cent. J. 12(1), 1–9 (2018).
  MedlineGoogle Scholar
• 37. Moreira Da Silva R, De Gaitani CM, Marques LMM et al. Characterization of casearin X metabolism by rat and human liver microsomes. Planta Med. 85(4), 282–291 (2019).
  MedlineGoogle Scholar
• 38. Li W, Zhang J, Wang Y, Hu F, Zhang Y. Metabolism of vesatolimod in rat, dog, and human liver microsomes: metabolic stability assessment, metabolite identification, and interspecies comparison. Drug Test Anal. 11(2), 240–249 (2019).
  Medline CASGoogle Scholar
• 39. Attwa MW, Abdelhameed AS, Alsaif NA, Kadi AA, AlRabiah H. A validated LC–MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes. RSC Adv. 12(31), 20387–20394 (2022).
  Medline CASGoogle Scholar
• 40. Gan X, Wilson MW, Beyett TS et al. Synthesis of deuterium-labelled amlexanox and its metabolic stability against mouse, rat, and human microsomes. J. Label. Compd. Radiopharm. 62(5), 202–208 (2019).
  Medline CASGoogle Scholar
• 41. Schneider D, Bier D, Holschbach M, Bauer A, Neumaier B. Species differences in microsomal metabolism of xanthine-derived A1 adenosine receptor ligands. Pharmaceuticals 14(3), 1–19 (2021).
  Google Scholar
• 42. Taneja I, Karsauliya K, Rashid M et al. Species differences between rat and human in vitro metabolite profile, in vivo predicted clearance, CYP450 inhibition and CYP450 isoforms that metabolize benzanthrone: implications in risk assessment. Food Chem. Toxicol. 111, 94–101 (2018).
  Medline CASGoogle Scholar
• 43. Salviati E, Sommella E, Carrizzo A et al. Characterization of phase I and phase II metabolites of hop (Humulus lupulus L.) bitter acids: in vitro and in vivo metabolic profiling by UHPLC-Q-Orbitrap. J. Pharm. Biomed. Anal. 201, 114107 (2021). •• Study demonstrated metabolism through phase I and phase II in interspecies liver microsomes.
  Medline CASGoogle Scholar
• 44. Tolleson WH, Doerge DR, Churchwell MI, Marques MM, Roberts DW. Metabolism of biochanin A and formononetin by human liver microsomes in vitro. J. Agric. Food Chem. 50(17), 4783–4790 (2002). •• Study describes liver microsomal study using different species.
  Medline CASGoogle Scholar
• 45. Siramshetty VB, Shah P, Kerns E et al. Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models. Sci. Rep. 10(1), 1–14 (2020).
  MedlineGoogle Scholar
• 46. Nguyen TTL, Kim JW, Choi HI, Maeng HJ, Koo TS. Development of an LC–MS/MS method for ARV-110, a PROTAC molecule, and applications to pharmacokinetic studies. Molecules 27(6), 1–15 (2022).
  Google Scholar
• 47. Attwa MW, Abdelhameed AS, Kadi AA. LC–MS/MS estimation of rociletinib levels in human liver microsomes: application to metabolic stability estimation. Drug Des. Devel. Ther. 15, 3915–3925 (2021).
  MedlineGoogle Scholar
• 48. Riyazuddin M, Valicherla GR, Husain A et al. Elucidation of pharmacokinetics of novel DNA ligase I inhibitor, S012-1332 in rats: integration of in vitro and in vivo findings. J. Pharm. Biomed. Anal. 162, 205–214 (2019).
  Medline CASGoogle Scholar